SCHEMBL1143740

SCHEMBL1143740

COc1ccc(-c2nnc(N)s2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 1.00
ALDH1A1 P00352 6/20 1.00
MAPT P10636 4/20 1.00
HSD17B10 Q99714 3/20 1.00
TP53 P04637 2/20 1.00
RAB9A P51151 7/20 0.68
NPC1 O15118 6/20 0.68
SMN1; SMN2 Q16637 5/20 0.68
LMNA P02545 3/20 0.65
L3MBTL1 Q9Y468 1/20 0.64
MGAM O43451 4/20 0.59
GAA P10253 4/20 0.59
SI P14410 4/20 0.59
MGAM2 Q2M2H8 4/20 0.59
NOTUM Q6P988 1/20 0.59
HPGD P15428 3/20 0.59
QPCT Q16769 2/20 0.57
QPCTL Q9NXS2 1/20 0.57
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27903833 0.98 KDM4E (0.96) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL6663651 0.86 KDM4E (0.75) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL23292523 0.81 KDM4E (0.69) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL9342320 0.81 KDM4E (0.68) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL17713905 0.80 KDM4E (0.76) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL20522413 0.80 KDM4E (0.64) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL6154686 0.80 NOTUM (0.71) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL6539262 0.80 KDM4E (0.97) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL13912997 0.79 KDM4E (0.66) KDM4EALDH1A1MAPTHSD17B10TP53
SCHEMBL22761303 0.79 KDM4E (0.73) KDM4EALDH1A1MAPTHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250364276-A1 TUNABLE LOW-COST PASSIVATION COATING FOR FACILITATING FLUXLESS BONDING OF COPPER SOLDER INTERCONNECTS IN FLIP CHIP ASSEMBLY UNIV NORTH TEXAS (US) 2025-11-27 US claimed
CN-119563048-A Passivation coating on copper metal surfaces for copper wire bonding applications 北德克萨斯大学 2025-03-04 CN claimed
US-20210071308-A1 SELECTIVE SURFACE FINISHING FOR CORROSION INHIBITION VIA CHEMICAL VAPOR DEPOSITION UNIVERSITY OF NORTH TEXAS 2021-03-11 US claimed
CN-108299964-A Anti-aging coating of insulation for outdoor box switchyard and preparation method thereof 河南龙翔电气股份有限公司 2018-07-20 CN claimed
EP-2526098-B1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-07-11 EP claimed
CN-106340344-B Non-aging insulation cable and preparation method thereof 河南开启电力实业有限公司 2017-12-01 CN claimed
CN-106373641-A Double-capacity electric cable and manufacture method therefor 河南开启电力实业有限公司 2017-02-01 CN claimed
CN-106340344-A Aging-resistant insulated cable and preparation method thereof 河南开启电力实业有限公司 2017-01-18 CN claimed
CN-106187945-A A kind of synthetic method of organic synthesis intermediate 辽宁师范大学 2016-12-07 CN claimed
CN-105694192-A High heat resistant and radiation resistant cable sheath material 临海市亚东特种电缆料厂 2016-06-22 CN claimed
CN-102875887-B Low-smoke halogen-free flame-retardant electric insulation material for cables LINHAI CITY YADONG SPECIAL CABLE MATERIAL FACTORY 2015-01-28 CN claimed
US-8470820-B2 Nitrogen-containing heteroaryl derivatives HOFFMAN-LA ROCHE INC. (US) 2013-06-25 US claimed
EP-1658072-A4 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2009-03-25 EP claimed
US-20070270426-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER INC. 2007-11-22 US claimed
US-7253195-B2 Compounds for the treatment of neurodegenerative disorders PFIZER INC (US) 2007-08-07 US claimed
EP-1658072-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-24 EP claimed
WO-2005020991-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS, INC. (US) 2005-03-10 WO claimed
US-20050043372-A1 Compounds for the treatment of neurodegenerative disorders PFIZER, INC. (US) 2005-02-24 US claimed
CN-122095010-A Silicone-based optically clear adhesives with corrosion resistance 2026-05-26 CN disclosed
EP-0005783-A1 Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments BAYER AG (DE) 1979-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270426-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS APP, BACE1, PSEN1 KDM4E 3582/4885ALDH1A1 2945/4885MAPT 9/4885
US-20050043372-A1 Compounds for the treatment of neurodegenerative disorders APP, BACE1, PSEN1 KDM4E 3582/4885ALDH1A1 2945/4885MAPT 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.